Outlook Therapeutics (OTLK) Non-Current Deffered Revenue (2015 - 2019)

Outlook Therapeutics (OTLK) has 5 years of Non-Current Deffered Revenue data on file, last reported at $3.5 million in Q2 2019.

• Non-Current Deffered Revenue for Q2 2019 came in at $3.5 million, up 15.41% year-over-year; the trailing twelve-month figure through Jun 2019 was $3.5 million (up 15.41% YoY), and the FY2018 annual result was $2.8 million, down 38.25% from the prior year.
• Non-Current Deffered Revenue eased to $3.5 million in Q2 2019 per OTLK's latest filing, from $4.1 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $6.4 million in Q3 2015 and troughed at $2.8 million in Q3 2018.
• A 5-year average of $4.4 million and a median of $4.5 million in 2017 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2018 and 2019: Non-Current Deffered Revenue sank 38.25% in 2018, then rose 23.46% in 2019.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $6.4 million in 2015, then dropped by 23.81% to $4.9 million in 2016, then decreased by 16.87% to $4.0 million in 2017, then advanced by 16.58% to $4.7 million in 2018, then declined by 24.84% to $3.5 million in 2019.
• Business Quant data shows OTLK's Non-Current Deffered Revenue at $3.5 million in Q2 2019, $4.1 million in Q1 2019, and $4.7 million in Q4 2018.